NL930075I2 - Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan. - Google Patents

Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan.

Info

Publication number
NL930075I2
NL930075I2 NL930075C NL930075C NL930075I2 NL 930075 I2 NL930075 I2 NL 930075I2 NL 930075 C NL930075 C NL 930075C NL 930075 C NL930075 C NL 930075C NL 930075 I2 NL930075 I2 NL 930075I2
Authority
NL
Netherlands
Prior art keywords
pyridylsulfinylbenzimidazoles
intermediates
substituted
compounds
preparation
Prior art date
Application number
NL930075C
Other languages
English (en)
Other versions
NL930075I1 (nl
Original Assignee
Haessle Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20334608&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NL930075(I2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Haessle Ab filed Critical Haessle Ab
Publication of NL930075I1 publication Critical patent/NL930075I1/nl
Publication of NL930075I2 publication Critical patent/NL930075I2/nl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/14—Prodigestives, e.g. acids, enzymes, appetite stimulants, antidyspeptics, tonics, antiflatulents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
NL930075C 1978-04-14 1993-06-16 Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan. NL930075I2 (nl)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE7804231A SE7804231L (sv) 1978-04-14 1978-04-14 Magsyrasekretionsmedel

Publications (2)

Publication Number Publication Date
NL930075I1 NL930075I1 (nl) 1993-09-16
NL930075I2 true NL930075I2 (nl) 1994-02-16

Family

ID=20334608

Family Applications (2)

Application Number Title Priority Date Filing Date
NL930075C NL930075I2 (nl) 1978-04-14 1993-06-16 Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan.
NL930074C NL930074I2 (nl) 1978-04-14 1993-06-16 Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan.

Family Applications After (1)

Application Number Title Priority Date Filing Date
NL930074C NL930074I2 (nl) 1978-04-14 1993-06-16 Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan.

Country Status (25)

Country Link
US (3) US4255431A (nl)
EP (1) EP0005129B1 (nl)
JP (2) JPS6034956B2 (nl)
AT (2) AT389995B (nl)
BG (1) BG61492B2 (nl)
CA (1) CA1127158A (nl)
CS (1) CS261851B2 (nl)
CY (1) CY1232A (nl)
DD (1) DD142882A5 (nl)
DE (1) DE2960293D1 (nl)
DK (1) DK150510C (nl)
FI (1) FI65067C (nl)
HK (1) HK15284A (nl)
HU (1) HU179022B (nl)
IE (1) IE48370B1 (nl)
LT (1) LT2274B (nl)
LU (2) LU88305I2 (nl)
MY (1) MY8500074A (nl)
NL (2) NL930075I2 (nl)
NO (5) NO152216C (nl)
NZ (1) NZ190203A (nl)
SE (1) SE7804231L (nl)
SG (1) SG63383G (nl)
SU (4) SU895292A3 (nl)
ZA (1) ZA791586B (nl)

Families Citing this family (372)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4359465A (en) * 1980-07-28 1982-11-16 The Upjohn Company Methods for treating gastrointestinal inflammation
CH644116A5 (de) * 1980-08-21 1984-07-13 Hoffmann La Roche Imidazolderivate.
IL66340A (en) * 1981-08-13 1986-08-31 Haessle Ab Pharmaceutical compositions comprising pyridylmethyl-thiobenzimidazole derivatives,certain such novel derivatives and their preparation
US4472409A (en) * 1981-11-05 1984-09-18 Byk Gulden Lomberg Chemische Fabrik Gesellschaft Mit Beschrankter Haftung 2-Pyridylmethyl thio(sulfinyl)benzimidazoles with gastric acid secretion inhibiting effects
JPS58135881A (ja) * 1981-11-05 1983-08-12 ビク−グルデン・ロムベルク・ヘミツシエ・フアブリク・ゲゼルシヤフト・ミト・ベシユレンクテル・ハフツング 置換ベンズイミダゾ−ル類、その製造方法と利用、およびこれを含む医薬
DE3216843C2 (de) * 1982-05-05 1986-10-23 Ludwig Heumann & Co GmbH, 8500 Nürnberg 3-Thiomethyl-pyridin-Derivate, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
SE8204879D0 (sv) * 1982-08-26 1982-08-26 Haessle Ab Novel chemical intermediates
SE8300736D0 (sv) * 1983-02-11 1983-02-11 Haessle Ab Novel pharmacologically active compounds
SE8301182D0 (sv) * 1983-03-04 1983-03-04 Haessle Ab Novel compounds
IL71664A (en) * 1983-05-03 1987-11-30 Byk Gulden Lomberg Chem Fab Fluoroalkoxy compounds,process for their preparation and pharmaceutical compositions containing the same
HU193408B (en) * 1983-05-03 1987-10-28 Byk Gulden Lomberg Chem Fqb Process for production of new tree-cycle compounds
CA1259070A (en) * 1983-07-01 1989-09-05 Upjohn Company (The) Substituted 2-¬monoannelated(3,4-,4,5-, and 5,6-)- pyridylalkylenesulfinyl|-benzimidazoles
US5077407A (en) * 1983-07-01 1991-12-31 The Upjohn Company Substituted 2-[monoannelated (3,4-,4,5-, and 5,6-) pyridylalkylenesulfinyl]benzimidazoles
DE3333314A1 (de) * 1983-09-15 1985-03-28 Hoechst Ag, 6230 Frankfurt Substituierte pyrido(1,2-c)imidazo(1,2-a)benzimidazole, verfahren zu ihrer herstellung, ihre verwendung sowie pharmazeutische praeparate auf basis dieser verbindungen
US4663347A (en) 1983-10-31 1987-05-05 Merck Frosst Canada, Inc. Benzofuran 2-carboxylic acid esters useful as inhibitors of leukotriene biosynthesis
US4575554A (en) * 1983-12-05 1986-03-11 The Upjohn Company Substituted 2-pyridylmethylthio- and sulfinyl-benzimidazoles as gastric antisecretory agents
ZW4585A1 (en) * 1984-04-19 1985-11-20 Hoffmann La Roche Imidazole derivatives
SE8403179D0 (sv) * 1984-06-13 1984-06-13 Haessle Ab New compounds
IL75400A (en) * 1984-06-16 1988-10-31 Byk Gulden Lomberg Chem Fab Dialkoxypyridine methyl(sulfinyl or sulfonyl)benzimidazoles,processes for the preparation thereof and pharmaceutical compositions containing the same
DE3585252D1 (de) 1984-07-06 1992-03-05 Fisons Plc Benzimidazole, und verfahren zu deren herstellung, deren formulierung und verwendung als magensaeuresekretionshemmende verbindungen.
SE8404065D0 (sv) * 1984-08-10 1984-08-10 Haessle Ab Novel biologically active compounds
JPS6150979A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
JPS6150978A (ja) * 1984-08-16 1986-03-13 Takeda Chem Ind Ltd ピリジン誘導体およびその製造法
US4619997A (en) * 1984-09-06 1986-10-28 The Upjohn Company Substituted 2-pyridylmethylthio and sulfinyl-benzimidazoles as gastric antisecretory agents
KR890000387B1 (ko) * 1984-09-24 1989-03-16 디 엎존 캄파니 2-(피리딜알켄술 피닐)벤즈 이미드아졸류의 n-치환 유도체의 제조방법
SE8405588D0 (sv) * 1984-11-08 1984-11-08 Haessle Ab New compounds
EP0187977B1 (en) * 1984-12-18 1990-08-29 Otsuka Pharmaceutical Co., Ltd. Tetrahydroquinoline derivatives, process for preparing the same and anti-peptic ulcer compositions containg the same
FI861772A (fi) * 1985-05-07 1986-11-08 Chemie Linz Ag Nya tieno(2,3-d)imidazolderivat och foerfarande for deras framstaellning.
EP0204215B1 (en) 1985-05-24 1993-08-11 G.D. Searle & Co. 2-[(1H-benzimidazol-2-ylsulfinyl)methyl]-benzenamines
US5869513A (en) * 1985-05-24 1999-02-09 G. D. Searle & Co. 2- (1H-benzimidazol-2-ylsulfinyl)methyl!benzenamines
CA1309557C (en) 1985-06-18 1992-10-27 Robert N. Young Leukotriene antagonists
US4738975A (en) * 1985-07-02 1988-04-19 Takeda Chemical Industries, Ltd. Pyridine derivatives, and use as anti-ulcer agents
AR243167A1 (es) 1985-08-24 1993-07-30 Hoechst Ag Procedimiento para la preparacion de toluidinas sustituidas.
JPS6261978A (ja) * 1985-09-12 1987-03-18 Otsuka Pharmaceut Co Ltd ５−フルオロ−１ｈ−ベンズイミダゾ−ル誘導体
SE8505112D0 (sv) * 1985-10-29 1985-10-29 Haessle Ab Novel pharmacological compounds
US5433959A (en) * 1986-02-13 1995-07-18 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
US6749864B2 (en) * 1986-02-13 2004-06-15 Takeda Chemical Industries, Ltd. Stabilized pharmaceutical composition
ES2032394T3 (es) 1986-02-20 1993-02-16 Hoechst Aktiengesellschaft Procedimiento para preparar derivados de tienoimidazol sustituidos.
WO1987005296A1 (en) * 1986-03-07 1987-09-11 Pfizer Inc. 2-[(2-pyridyl)methylsulfinyl]thienoimidazoles and related compounds as antiulcer agents
ATE90076T1 (de) 1986-03-27 1993-06-15 Merck Frosst Canada Inc Tetrahydrocarbazole ester.
GB2189698A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
GB2189699A (en) * 1986-04-30 1987-11-04 Haessle Ab Coated acid-labile medicaments
US4687775A (en) * 1986-07-17 1987-08-18 G. D. Searle & Co. 2-[(Imidazo[1,2-a]pyridinylmethyl)sulfinyl]-1H-benzimidazoles
US4772619A (en) * 1986-07-17 1988-09-20 G. D. Searle & Co. [(1H-benzimidazol-2-ylsulfinyl)methyl]-2-pyridinamines
US4721718A (en) * 1986-08-18 1988-01-26 G. D. Searle & Co. 2-[(imidazo[1,2-a]pyridin-3-ylmethyl)sulfinyl]-1H-benzimidazoles useful in the treatment and prevention of ulcers
CA1256109A (en) * 1986-09-10 1989-06-20 Franz Rovenszky Process for the preparation of derivatives of 4, 5-dihydrooxazoles
SE8604566D0 (sv) * 1986-10-27 1986-10-27 Haessle Ab Novel compunds
FI90544C (fi) * 1986-11-13 1994-02-25 Eisai Co Ltd Menetelmä lääkeaineina käyttökelpoisten 2-pyridin-2-yyli-metyylitio- ja sulfinyyli-1H-bensimidatsolijohdannaisten valmistamiseksi
EP0786461A1 (en) * 1986-11-13 1997-07-30 Eisai Co., Ltd. Pyridine derivatives, pharmaceutical compositions comprising the same, the use of the same for the manufacture of medicaments having therapeutic or preventative value, and a process for preparing the same
SE8604998D0 (sv) 1986-11-21 1986-11-21 Haessle Ab Novel pharmacological compounds
NZ234564A (en) 1986-11-21 1991-04-26 Haessle Ab 1-substituted benzimidazoles and pharmaceutical compositions
DE3639926A1 (de) * 1986-11-22 1988-06-01 Hoechst Ag Substituierte thienoimidazoltoluidin-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer
FI91754C (fi) * 1986-12-02 1994-08-10 Tanabe Seiyaku Co Analogiamenetelmä lääkeaineena käyttökelpoisen imidatsolijohdannaisen valmistamiseksi
JPS63230633A (ja) * 1987-03-19 1988-09-27 Nippon Chemiphar Co Ltd 胃腸の細胞保護剤
DE3719783A1 (de) * 1987-06-13 1988-12-22 Hoechst Ag Verfahren zur herstellung von 5-phenylsulfinyl-1h-2-(methoxycarbonylamino)- benzimidazol
FI96860C (fi) * 1987-06-17 1996-09-10 Eisai Co Ltd Analogiamenetelmä lääkeaineena käytettävän pyridiinijohdannaisen valmistamiseksi
JP2718945B2 (ja) * 1987-06-17 1998-02-25 エーザイ株式会社 ピリジン誘導体及びそれを含有する潰瘍治療剤
DE3723327A1 (de) * 1987-07-15 1989-02-02 Hoechst Ag Substituierte thienoimidazol-derivate, verfahren zu ihrer herstellung, sie enthaltende pharmazeutische zubereitungen und ihre verwendung als magensaeuresekretionshemmer, magenschutzmittel sowie als medikament gegen intestinale entzuendungen
DK171989B1 (da) * 1987-08-04 1997-09-08 Takeda Chemical Industries Ltd Fremgangsmåde til fremstilling af 2-(2-pyridylmethylsulfinyl)-benzimidazoler
US5124158A (en) * 1988-06-30 1992-06-23 The Upjohn Company Transdermal antisecretory agents for gastrointestinal disease
US5223515A (en) * 1988-08-18 1993-06-29 Takeda Chemical Industries, Ltd. Injectable solution containing a pyridyl methylsulfinylbenzimidazole
AU4057189A (en) * 1988-08-23 1990-03-23 Aktiebolaget Hassle Treatment of glaucoma and related disorders in the human eye with pyridinylmethyl (sulfinyl or thio)benzimidazoles
US5075323A (en) * 1988-08-24 1991-12-24 Aktiebolaget Hassle Compounds including omeprazole in the treatment of glaucoma
KR920003928B1 (ko) * 1988-09-20 1992-05-18 히사미쯔세이야꾸 가부시기가이샤 신규의 디벤즈[b,e]옥세핀유도체
AT391693B (de) * 1988-11-15 1990-11-12 Cl Pharma Verfahren zur herstellung von 3-5-dimethyl-4methoxypyridinderivaten sowie neues zwischenprodukt hierfuer
IE64199B1 (en) * 1988-12-22 1995-07-12 Haessle Ab Compound with gastric acid inhibitory effect and process for its preparation
SE8804629D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New therapeutically active compounds
SE8804628D0 (sv) 1988-12-22 1988-12-22 Ab Haessle New compounds
JP2694361B2 (ja) * 1989-02-09 1997-12-24 アストラ アクチエボラグ 抗菌剤
GB2239453A (en) * 1989-11-27 1991-07-03 Haessle Ab Omeprazole
US5049674A (en) * 1989-12-20 1991-09-17 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US5274099A (en) * 1989-12-20 1993-12-28 Aktiebolaget Hassle Therapeutically active fluoro substituted benzimidazoles
US4965269A (en) * 1989-12-20 1990-10-23 Ab Hassle Therapeutically active chloro substituted benzimidazoles
KR930000861B1 (ko) * 1990-02-27 1993-02-08 한미약품공업 주식회사 오메프라졸 직장투여 조성물
HU217025B (hu) 1990-04-04 1999-11-29 Chiron Corp. Hepatitis C vírus-(HCV) antigénkészítmények az anti-HCV-antitestek kimutatására immunoassay-kben
SE9002043D0 (sv) * 1990-06-07 1990-06-07 Astra Ab Improved method for synthesis
PL166209B1 (pl) * 1990-06-20 1995-04-28 Astra Ab Sposób wytwarzania nowych pochodnych benzimidazolu PL
SE9002206D0 (sv) 1990-06-20 1990-06-20 Haessle Ab New compounds
US5061805A (en) * 1990-08-10 1991-10-29 Reilly Industries, Inc. Process for preparing 2-methyl-3,5-dialkylpyridines by dealkylation with sulfur
CA2052698A1 (en) * 1990-10-11 1992-04-12 Roger G. Berlin Treatment of peptic ulcer
US5428033A (en) 1990-10-12 1995-06-27 Merck Frosst Canada, Inc. Saturated hydroxyalkylquinoline acids as leukotriene antagonists
EP0481764B1 (en) 1990-10-17 2000-03-29 Takeda Chemical Industries, Ltd. Pyridine derivatives, their production and use
ES2026761A6 (es) * 1990-10-31 1992-05-01 Genesis Para La Investigacion Procedimiento de obtencion del omeprazol.
NZ244301A (en) * 1991-09-20 1994-08-26 Merck & Co Inc Preparation of 2-pyridylmethylsulphinylbenzimidazole and pyridoimidazole derivatives from the corresponding sulphenyl compounds
FR2692146B1 (fr) * 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
WO1994001107A1 (en) * 1992-07-08 1994-01-20 Monsanto Company Benzimidazoles for alleviating stomach ulcers in swine
ATE144421T1 (de) * 1992-07-28 1996-11-15 Astra Ab Injizierbares arzneimittel und satz, die omoprazol oder verwandte verbindungenenthalten
SE9301830D0 (sv) 1993-05-28 1993-05-28 Ab Astra New compounds
US6875872B1 (en) 1993-05-28 2005-04-05 Astrazeneca Compounds
SE9302395D0 (sv) * 1993-07-09 1993-07-09 Ab Astra New pharmaceutical formulation
SE9302396D0 (sv) * 1993-07-09 1993-07-09 Ab Astra A novel compound form
US5410054A (en) * 1993-07-20 1995-04-25 Merck Frosst Canada, Inc. Heteroaryl quinolines as inhibitors of leukotriene biosynthesis
TW280770B (nl) 1993-10-15 1996-07-11 Takeda Pharm Industry Co Ltd
CA2175235A1 (en) * 1993-10-29 1995-05-04 Takeshi Kawakita Pyridine compound and medicinal use thereof
US5502195A (en) * 1993-11-04 1996-03-26 Slemon; Clarke Sulfoxide-carboxylate intermediates of omeprazole and lansoprazole
US5374730A (en) * 1993-11-04 1994-12-20 Torcan Chemical Ltd. Preparation of omeprazole and lansoprazole
KR0142815B1 (ko) * 1994-12-02 1998-07-15 정도언 신규한 5-피롤릴-6-할로게노-2피리딜메틸설피닐벤즈이미다졸 유도체
KR0179401B1 (ko) * 1994-02-28 1999-03-20 송택선 신규한 5-피롤릴-2-피리딜메틸설피닐벤즈이미다졸 유도체
WO1995029897A1 (en) 1994-04-29 1995-11-09 G.D. Searle & Co. METHOD OF USING (H+/K+) ATPase INHIBITORS AS ANTIVIRAL AGENTS
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
EP0723436B1 (en) * 1994-07-08 2001-09-26 AstraZeneca AB Multiple unit tableted dosage form i
SE504459C2 (sv) * 1994-07-15 1997-02-17 Astra Ab Förfarande för framställning av substituerade sulfoxider
GB9423970D0 (en) * 1994-11-28 1995-01-11 Astra Ab Oxidation
GB9423968D0 (en) * 1994-11-28 1995-01-11 Astra Ab Resolution
SE9500422D0 (sv) * 1995-02-06 1995-02-06 Astra Ab New oral pharmaceutical dosage forms
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
JP3015702B2 (ja) * 1995-02-21 2000-03-06 株式会社アラクス イミダゾール誘導体及びそれらの薬剤として許容される酸付加塩及びその製造法並びにそれらを有効成分とする抗潰瘍剤
JP3046924B2 (ja) * 1995-03-27 2000-05-29 株式会社アラクス イミダゾリン誘導体又はそれらの可能な互変異性体及びそれらの製造方法並びにそれらを有効成分とする創傷治療薬
US5708017A (en) * 1995-04-04 1998-01-13 Merck & Co., Inc. Stable, ready-to-use pharmaceutical paste composition containing proton pump inhibitors
HRP960232A2 (en) * 1995-07-03 1998-02-28 Astra Ab A process for the optical purification of compounds
US5686588A (en) * 1995-08-16 1997-11-11 Yoo; Seo Hong Amine acid salt compounds and process for the production thereof
US5824339A (en) * 1995-09-08 1998-10-20 Takeda Chemical Industries, Ltd Effervescent composition and its production
ATE262332T1 (de) * 1995-09-21 2004-04-15 Pharma Pass Ii Llc Lansoprazolhaltige arzneizusammensetzung und herstellungsverfahren
SE521100C2 (sv) * 1995-12-15 2003-09-30 Astra Ab Förfarande för framställning av en bensimidazolförening
KR970032861A (ko) * 1995-12-29 1997-07-22 김준웅 헬리코박터 피로리 제거용 약제 투여방법
US20050054682A1 (en) * 1996-01-04 2005-03-10 Phillips Jeffrey O. Pharmaceutical compositions comprising substituted benzimidazoles and methods of using same
US5840737A (en) 1996-01-04 1998-11-24 The Curators Of The University Of Missouri Omeprazole solution and method for using same
US6645988B2 (en) * 1996-01-04 2003-11-11 Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6489346B1 (en) 1996-01-04 2002-12-03 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and method of using same
US6699885B2 (en) 1996-01-04 2004-03-02 The Curators Of The University Of Missouri Substituted benzimidazole dosage forms and methods of using same
SE9600070D0 (sv) 1996-01-08 1996-01-08 Astra Ab New oral pharmaceutical dosage forms
AU1538397A (en) * 1996-02-06 1997-08-28 Pdi-Research Laboratories, Inc. Synthesis of omeprazole-type pyridine derivatives and intermediates thereof
US6623759B2 (en) * 1996-06-28 2003-09-23 Astrazeneca Ab Stable drug form for oral administration with benzimidazole derivatives as active ingredient and process for the preparation thereof
US5625069A (en) * 1996-07-22 1997-04-29 Development Center For Biotechnology Process for preparing 2-cyano-3,5-dimethyl-4-methoxypyridine
US6599927B2 (en) 1996-10-11 2003-07-29 Astrazeneca Ab Use of an H+, K+-ATPase inhibitor in the treatment of Widal's Syndrome
TW385306B (en) * 1996-11-14 2000-03-21 Takeda Chemical Industries Ltd Method for producing crystals of benzimidazole derivatives
SE510666C2 (sv) * 1996-12-20 1999-06-14 Astra Ab Nya Kristallmodifikationer
CA2204580A1 (en) * 1997-05-06 1998-11-06 Michel Zoghbi Synthesis of pharmaceutically useful pyridine derivatives
US6437139B1 (en) 1997-05-06 2002-08-20 Pdi-Research Laboratories, Inc. Synthesis of pharmaceutically useful pyridine derivatives
KR100463031B1 (ko) * 1997-05-26 2005-04-06 동아제약주식회사 5-메톡시-2-[3,5-디메틸-4-메톡시피리딜메틸)설피닐]-1h-벤즈이미다졸의신규제조방법
SE9702000D0 (sv) * 1997-05-28 1997-05-28 Astra Ab New pharmaceutical formulation
US6747155B2 (en) 1997-05-30 2004-06-08 Astrazeneca Ab Process
SE510650C2 (sv) 1997-05-30 1999-06-14 Astra Ab Ny förening
AU6551198A (en) * 1997-05-30 1998-12-30 Dr. Reddy's Research Foundation Novel benzimidazole derivatives as antiulcer agents, process for their preparation and pharmaceutical compositions containing them
SE510643C2 (sv) 1997-06-27 1999-06-14 Astra Ab Termodynamiskt stabil omeprazol natrium form B
DE69814862T2 (de) * 1997-07-11 2004-02-19 Eisai Co., Ltd. Verfahren zur herstellung von pyridinderivaten
SI9700186B (sl) 1997-07-14 2006-10-31 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Nova farmacevtska oblika z nadzorovanim sproscanjem zdravilnih ucinkovin
EP1003554B1 (en) 1997-07-25 2004-11-03 ALTANA Pharma AG Proton pump inhibitor in therapeutic combination with antibacterial substances
US6296876B1 (en) 1997-10-06 2001-10-02 Isa Odidi Pharmaceutical formulations for acid labile substances
US7230014B1 (en) * 1997-10-14 2007-06-12 Eisai Co., Ltd. Pharmaceutical formulation comprising glycine as a stabilizer
US6174548B1 (en) 1998-08-28 2001-01-16 Andrx Pharmaceuticals, Inc. Omeprazole formulation
US6096340A (en) * 1997-11-14 2000-08-01 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9704183D0 (sv) * 1997-11-14 1997-11-14 Astra Ab New process
JP4546643B2 (ja) 1997-12-08 2010-09-15 ニコメッド ゲゼルシャフト ミット ベシュレンクテル ハフツング 酸不安定な活性化合物を含有する新規の坐剤形
DE19754324A1 (de) * 1997-12-08 1999-06-10 Byk Gulden Lomberg Chem Fab Neue Darreichungsform enthaltend einen säurelabilen Wirkstoff
SE9704869D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulaton II
SE9704870D0 (sv) * 1997-12-22 1997-12-22 Astra Ab New pharmaceutical formulation I
US6159968A (en) * 1998-01-15 2000-12-12 University Of Cincinnati Activation of chloride channels for correction of defective chloride transport
US6350876B2 (en) 1998-01-26 2002-02-26 Kuraray Co., Ltd. 4-chloro-3,5-dimethyl-2-sulfonyl pyridines
KR100396431B1 (ko) * 1998-01-26 2003-09-02 가부시키가이샤 구라레 2-술포닐피리딘 유도체 및 2-[((2-피리딜)메틸)티오]-1ｈ-벤즈이
IT1299198B1 (it) 1998-03-05 2000-02-29 Nicox Sa Sali nitrati di farmaci antiulcera
US6328994B1 (en) 1998-05-18 2001-12-11 Takeda Chemical Industries, Ltd. Orally disintegrable tablets
US6303787B1 (en) 1998-05-27 2001-10-16 Natco Pharma Limited Intermediates and an improved process for the preparation of Omeprazole employing the said intermediates
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
AU4387799A (en) * 1998-06-26 2000-01-17 Russinsky Limited Pyridine building blocks as intermediates in the synthesis of pharmaceutically active compounds
SI20019A (sl) 1998-07-13 2000-02-29 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Izboljšan postopek sinteze 5-metoksi -2-/(4-metoksi-3,5-dimetil-2-piridil)metil/ sulfinil-1H-benzimidazola
US6093734A (en) * 1998-08-10 2000-07-25 Partnership Of Michael E. Garst, George Sachs, And Jai Moo Shin Prodrugs of proton pump inhibitors
CN100396675C (zh) 1998-08-10 2008-06-25 加利福尼亚州大学董事会 质子泵抑制剂的前药
US6166213A (en) * 1998-08-11 2000-12-26 Merck & Co., Inc. Omeprazole process and compositions thereof
US6191148B1 (en) * 1998-08-11 2001-02-20 Merck & Co., Inc. Omerazole process and compositions thereof
SI1105105T1 (sl) 1998-08-12 2006-08-31 Altana Pharma Ag Oralna dajalna oblika za piridin-2-ilmetilsulfinil-1J-benzimidazole
DE19843413C1 (de) * 1998-08-18 2000-03-30 Byk Gulden Lomberg Chem Fab Neue Salzform von Pantoprazol
US6733778B1 (en) 1999-08-27 2004-05-11 Andrx Pharmaceuticals, Inc. Omeprazole formulation
SE9803772D0 (sv) 1998-11-05 1998-11-05 Astra Ab Pharmaceutical formulation
WO2000027841A1 (en) * 1998-11-06 2000-05-18 Dong-A Pharmaceutical Co., Ltd. Method of preparing sulfide derivatives
IL142703A (en) 1998-11-10 2006-04-10 Astrazeneca Ab Crystalline form of omeprazole
UA72748C2 (en) * 1998-11-10 2005-04-15 Astrazeneca Ab A novel crystalline form of omeprazole
JP3926936B2 (ja) * 1998-11-16 2007-06-06 エーザイ・アール・アンド・ディー・マネジメント株式会社 スルホキシド誘導体・アセトン錯体およびその製造法
SE9900274D0 (sv) 1999-01-28 1999-01-28 Astra Ab New compound
US6852739B1 (en) * 1999-02-26 2005-02-08 Nitromed Inc. Methods using proton pump inhibitors and nitric oxide donors
TWI243672B (en) 1999-06-01 2005-11-21 Astrazeneca Ab New use of compounds as antibacterial agents
AU775995B2 (en) 1999-06-07 2004-08-19 Nycomed Gmbh Novel preparation and administration form comprising an acid-labile active compound
IL130602A0 (en) 1999-06-22 2000-06-01 Dexcel Ltd Stable benzimidazole formulation
US6555139B2 (en) 1999-06-28 2003-04-29 Wockhardt Europe Limited Preparation of micron-size pharmaceutical particles by microfluidization
US6245913B1 (en) 1999-06-30 2001-06-12 Wockhardt Europe Limited Synthetic procedure for 5-methoxy-2-[(4-methoxy-3,5-dimethyl-2-pyridinyl)-methylthio]-IH-benzimidazole hydrochloride and its conversion to omeprazole
US6312712B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Method of improving bioavailability
US6262086B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Pharmaceutical unit dosage form
US6262085B1 (en) 1999-08-26 2001-07-17 Robert R. Whittle Alkoxy substituted Benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6780880B1 (en) 1999-08-26 2004-08-24 Robert R. Whittle FT-Raman spectroscopic measurement
US6316020B1 (en) 1999-08-26 2001-11-13 Robert R. Whittle Pharmaceutical formulations
RO122491B1 (ro) * 1999-08-26 2009-07-30 Applied Analytical Industries, Inc. Derivaţi de benzimidazol, alcoxi substituiţi, compoziţii farmaceutice care îi conţin şi utilizarea acestora
US6326384B1 (en) 1999-08-26 2001-12-04 Robert R. Whittle Dry blend pharmaceutical unit dosage form
US6312723B1 (en) 1999-08-26 2001-11-06 Robert R. Whittle Pharmaceutical unit dosage form
US6369087B1 (en) 1999-08-26 2002-04-09 Robert R. Whittle Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
US6268385B1 (en) 1999-08-26 2001-07-31 Robert R. Whittle Dry blend pharmaceutical formulations
EP1595879A3 (en) * 1999-08-26 2010-01-27 aaiPharma Inc. Alkoxy substituted benzimidazole compounds, pharmaceutical preparations containing the same, and methods of using the same
AU6937700A (en) * 1999-08-26 2001-03-19 Applied Analytical Industries, Inc. Ft-raman spectroscopic measurement of omeprazole isomer ratio in a composition
US6228400B1 (en) 1999-09-28 2001-05-08 Carlsbad Technology, Inc. Orally administered pharmaceutical formulations of benzimidazole derivatives and the method of preparing the same
SE9903831D0 (sv) * 1999-10-22 1999-10-22 Astra Ab Formulation of substituted benzimidazoles
DE19951960C2 (de) 1999-10-28 2002-06-27 Gruenenthal Gmbh Verfahren zur Herstellung als Ulkustherapeutika geeigneter Benzimidazol-Derivate
CA2290893C (en) 1999-11-16 2007-05-01 Bernard Charles Sherman Magnesium omeprazole
DE19959419A1 (de) 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
US6420384B2 (en) * 1999-12-17 2002-07-16 Ariad Pharmaceuticals, Inc. Proton pump inhibitors
US6787342B2 (en) 2000-02-16 2004-09-07 Merial Limited Paste formulations
SE0000773D0 (sv) * 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
SE0000774D0 (sv) 2000-03-08 2000-03-08 Astrazeneca Ab New formulation
US6306435B1 (en) 2000-06-26 2001-10-23 Yung Shin Pharmaceutical Industrial Co. Ltd. Oral pharmaceutical preparation embedded in an oily matrix and methods of making the same
SE0002476D0 (sv) 2000-06-30 2000-06-30 Astrazeneca Ab New compounds
US6544556B1 (en) 2000-09-11 2003-04-08 Andrx Corporation Pharmaceutical formulations containing a non-steroidal antiinflammatory drug and a proton pump inhibitor
US20020064555A1 (en) * 2000-09-29 2002-05-30 Dan Cullen Proton pump inhibitor formulation
PT1341524E (pt) 2000-12-07 2011-12-30 Nycomed Gmbh Preparação farmacêutica na forma de uma pasta compreendendo um ingrediente activo lábil a ácido
US7357943B2 (en) 2000-12-07 2008-04-15 Nycomed Gmbh Pharmaceutical preparation in the form of a suspension comprising an acid-labile active ingredient
ATE541564T1 (de) 2000-12-07 2012-02-15 Nycomed Gmbh Schnell zerfallende tablette mit einem säurelabilen wirkstoff
CN1876647A (zh) 2001-02-02 2006-12-13 特瓦制药工业有限公司 苯并咪唑化合物产品
US6645946B1 (en) 2001-03-27 2003-11-11 Pro-Pharmaceuticals, Inc. Delivery of a therapeutic agent in a formulation for reduced toxicity
SE0101379D0 (sv) 2001-04-18 2001-04-18 Diabact Ab Komposition som hämmar utsöndring av magsyra
SI20875A (sl) * 2001-04-25 2002-10-31 LEK, tovarna farmacevtskih in kemi�nih izdelkov, d.d. Kristalna oblika omeprazola
US8206741B2 (en) 2001-06-01 2012-06-26 Pozen Inc. Pharmaceutical compositions for the coordinated delivery of NSAIDs
WO2002098352A2 (en) * 2001-06-01 2002-12-12 Pozen Inc. PHARMACEUTICAL COMPOSITIONS FOR THE COORDINATED DELIVERY OF NSAIDs
DE10140492A1 (de) 2001-08-17 2003-08-14 Gruenenthal Gmbh Hydrate von gegebenenfalls substituierten 2-(2-Pyridinyl)methylthio-1H-benzimidazolen und Verfahren zu ihrer Herstellung
SE0102993D0 (sv) 2001-09-07 2001-09-07 Astrazeneca Ab New self emulsifying drug delivery system
CA2445513A1 (en) * 2001-09-18 2003-03-27 Zeria Pharmaceutical Co., Ltd. Benzimidazole derivatives
US8101209B2 (en) 2001-10-09 2012-01-24 Flamel Technologies Microparticulate oral galenical form for the delayed and controlled release of pharmaceutical active principles
US8105626B2 (en) 2001-10-17 2012-01-31 Takeda Pharmaceutical Company Limited Granules containing acid-unstable chemical in large amount
US7855082B1 (en) 2001-10-31 2010-12-21 Astrazeneca Ab Raman spectroscopic method for determining the ratio of 5-methoxy and 6-methoxy isomers of omeprazole
MXPA04007169A (es) * 2002-01-25 2004-10-29 Santarus Inc Suministro transmucosal de inhibidores de bomba de protones.
CA2474246C (en) * 2002-03-05 2010-06-29 Astrazeneca Ab Alkylammonium salts of omeprazole and esomeprazole
IL164221A0 (en) 2002-04-09 2005-12-18 Flamel Tech Sa Oral pharmaceutical formulation in the form of aqueous suspension of microcapsules for modified release of amoxicillim
CA2480826C (fr) 2002-04-09 2012-02-07 Flamel Technologies Formulation pharmaceutique orale sous forme de suspension aqueuse de microcapsules permettant la liberation modifiee de principe(s) actif(s)
US20030228363A1 (en) * 2002-06-07 2003-12-11 Patel Mahendra R. Stabilized pharmaceutical compositons containing benzimidazole compounds
US20040034078A1 (en) * 2002-06-14 2004-02-19 Agouron Pharmaceuticals, Inc. Benzimidazole inhibitors of poly(ADP-ribosyl) polymerase
US6897227B2 (en) * 2002-07-19 2005-05-24 Winston Pharmaceuticals, Inc. Prodrugs of proton pump inhibitors
TW200410955A (en) 2002-07-29 2004-07-01 Altana Pharma Ag Novel salt of (S)-PANTOPRAZOLE
US7211590B2 (en) * 2002-08-01 2007-05-01 Nitromed, Inc. Nitrosated proton pump inhibitors, compositions and methods of use
SE0203065D0 (sv) 2002-10-16 2002-10-16 Diabact Ab Gastric acid secretion inhibiting composition
MY148805A (en) 2002-10-16 2013-05-31 Takeda Pharmaceutical Controlled release preparation
AU2003273000A1 (en) 2002-10-16 2004-05-04 Takeda Pharmaceutical Company Limited Stable solid preparations
SE0203092D0 (en) * 2002-10-18 2002-10-18 Astrazeneca Ab Method for the synthesis of a benzimidazole compound
FR2845915B1 (fr) 2002-10-21 2006-06-23 Negma Gild Utilisation du tenatoprazole pour le traitement du reflux gastro-oesophagien
EA200500673A1 (ru) * 2002-10-22 2005-12-29 Рэнбакси Лабораториз Лимитед Аморфная форма соли эзомепразола, способ ее получения и фармацевтическая композиция на её основе
DE10254167A1 (de) 2002-11-20 2004-06-09 Icon Genetics Ag Verfahren zur Kontrolle von zellulären Prozessen in Pflanzen
SI1575941T1 (sl) 2002-12-06 2012-08-31 Nycomed Gmbh Postopek za pripravo (S)-pantoprazola
US7452998B2 (en) 2002-12-06 2008-11-18 Nycomed Gmbh Process for preparing optically pure active compounds
FR2848555B1 (fr) 2002-12-16 2006-07-28 Negma Gild Enantiomere(-)du tenatoprazole et son application en therapeutique
CA2510849A1 (en) * 2002-12-19 2004-07-08 Teva Pharmaceutical Industries Ltd Solid states of pantoprazole sodium, processes for preparing them and processes for preparing known pantoprazole sodium hydrates
US20040166162A1 (en) * 2003-01-24 2004-08-26 Robert Niecestro Novel pharmaceutical formulation containing a proton pump inhibitor and an antacid
CA2517005A1 (en) * 2003-02-20 2004-09-02 Santarus, Inc. A novel formulation, omeprazole antacid complex-immediate release for rapid and sustained suppression of gastric acid
US20040185119A1 (en) * 2003-02-26 2004-09-23 Theuer Richard C. Method and compositions for treating gastric hyperacidity while diminishing the likelihood of producing vitamin deficiency
US20040235904A1 (en) * 2003-03-12 2004-11-25 Nina Finkelstein Crystalline and amorphous solids of pantoprazole and processes for their preparation
EP1611901B1 (en) * 2003-03-13 2013-07-10 Eisai R&D Management Co., Ltd. Preventive or remedy for teeth grinding
US20040185092A1 (en) * 2003-03-18 2004-09-23 Yih Ming Hsiao Pharmaceutical preparations of omeprazole and/or clarithromycin for oral use
EP1608649A2 (fr) * 2003-03-28 2005-12-28 Sidem Pharma SA Procede de preparation enantioselective de derives de sulfoxydes.
FR2852956B1 (fr) * 2003-03-28 2006-08-04 Negma Gild Procede de preparation enantioselective de derives de sulfoxydes
CL2004000983A1 (es) 2003-05-08 2005-03-04 Altana Pharma Ag Composicion farmaceutica oral en forma de tableta que comprende a pantoprazol magnetico dihidratado, en donde la forma de tableta esta compuesto por un nucleo, una capa intermedia y una capa exterior; y uso de la composicion farmaceutica en ulceras y
PE20050150A1 (es) 2003-05-08 2005-03-22 Altana Pharma Ag Una forma de dosificacion que contiene (s)-pantoprazol como ingrediente activo
WO2004101533A1 (en) * 2003-05-12 2004-11-25 Janssen Pharmaceutica, N.V. 1, 3, 4-benzotriazepin-2-one salts and their use as cck receptor ligands
MXPA05013316A (es) * 2003-06-10 2006-03-17 Teva Pharma Proceso para preparar bencimidazoles 2[-(piridinil)metil]sulfinil-sustituidos y derivados clorados novedosos de pantoprazol.
WO2004112756A1 (en) 2003-06-26 2004-12-29 Isa Odidi Proton pump-inhibitor-containing capsules which comprise subunits differently structured for a delayed release of the active ingredient
NZ544173A (en) * 2003-07-15 2009-04-30 Alevium Pharmaceuticals Inc Process for preparing isomerically pure prodrugs of benzimidazole derivative proton pump inhibitors
AR045061A1 (es) * 2003-07-18 2005-10-12 Santarus Inc Formulacion farmaceutica y metodo para tratar trastornos gastrointestinales causados por acido
WO2005007115A2 (en) * 2003-07-18 2005-01-27 Santarus, Inc. Pharmaceutical composition for inhibiting acid secretion
US8993599B2 (en) 2003-07-18 2015-03-31 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
MXPA06002443A (es) * 2003-09-03 2006-08-31 Agi Therapeutics Ltd Formulaciones inhibidoras de la bomba de protones y metodos para preparar y utilizar tales formulaciones.
SE0302381D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts I
SE0302382D0 (sv) 2003-09-04 2003-09-04 Astrazeneca Ab New salts II
TWI372066B (en) 2003-10-01 2012-09-11 Wyeth Corp Pantoprazole multiparticulate formulations
WO2005039640A1 (en) * 2003-10-03 2005-05-06 Allergan Inc. Compositions comprising trefoil factor family peptides and/or mucoadhesives and proton pump inhibitor prodrugs
US20050075371A1 (en) * 2003-10-03 2005-04-07 Allergan, Inc. Methods and compositions for the oral administration of prodrugs of proton pump inhibitors
US20070202119A1 (en) * 2003-10-24 2007-08-30 Ashdown Martin L Method Of Therapy
US20070292498A1 (en) * 2003-11-05 2007-12-20 Warren Hall Combinations of proton pump inhibitors, sleep aids, buffers and pain relievers
WO2005077936A1 (en) 2004-02-11 2005-08-25 Ulkar Kimya Sanayii Ve Ticaret A.S. Pyridine benzimidazole sulfoxides with high purity
JP2007523163A (ja) * 2004-02-18 2007-08-16 アラーガン、インコーポレイテッド プロトンポンプインヒビターのプロドラッグの投与のための方法および組成物
US20070161679A1 (en) * 2004-02-18 2007-07-12 Allergan, Inc. Method and compositions for the intravenous administration of compounds related to proton pump inhibitors
SE0400410D0 (sv) 2004-02-20 2004-02-20 Astrazeneca Ab New compounds
US20080287502A1 (en) * 2004-03-30 2008-11-20 Dermatrends, Inc. Transdermal Administration of Proton Pump Inhibitors
WO2005105786A1 (en) 2004-04-28 2005-11-10 Hetero Drugs Limited A process for preparing pyridinylmethyl-1h- benzimidazole compounds in enantiomerically enriched form or as single enantiomers
US8815916B2 (en) 2004-05-25 2014-08-26 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US8906940B2 (en) 2004-05-25 2014-12-09 Santarus, Inc. Pharmaceutical formulations useful for inhibiting acid secretion and methods for making and using them
US20050267157A1 (en) * 2004-05-28 2005-12-01 David White Magnesium-S-omeprazole
DE602004025386D1 (de) 2004-05-28 2010-03-18 Hetero Drugs Ltd Neue stereoselektive synthese von benzimidazolsulfoxiden
WO2005118569A1 (en) * 2004-06-02 2005-12-15 Altana Pharma Ag Process for the preparation of pyridin-2-ylmethylsulphinyl-1h-benzimidazol compounds
US8394409B2 (en) 2004-07-01 2013-03-12 Intellipharmaceutics Corp. Controlled extended drug release technology
US20060024362A1 (en) * 2004-07-29 2006-02-02 Pawan Seth Composition comprising a benzimidazole and process for its manufacture
US10624858B2 (en) 2004-08-23 2020-04-21 Intellipharmaceutics Corp Controlled release composition using transition coating, and method of preparing same
EP2264025B1 (en) 2004-09-13 2013-11-06 Takeda Pharmaceutical Company Limited Method for producing lansoprazole
US8541026B2 (en) 2004-09-24 2013-09-24 Abbvie Inc. Sustained release formulations of opioid and nonopioid analgesics
EP2417986A1 (en) 2004-11-22 2012-02-15 Anadis Ltd. Bioactive compositions
CN101111233A (zh) 2004-12-23 2008-01-23 兰贝克赛实验室有限公司 稳定的口服苯并咪唑组合物及其制备方法
US20080279951A1 (en) * 2005-02-02 2008-11-13 Rajesh Gandhi Stable Oral Benzimidazole Compositions Prepared by Non-Aqueous Layering Process
WO2006090845A1 (ja) 2005-02-25 2006-08-31 Takeda Pharmaceutical Company Limited 顆粒の製造方法
US7981908B2 (en) 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
US7803817B2 (en) 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
WO2006134605A1 (en) 2005-06-15 2006-12-21 Hetero Drugs Limited Amorphous esomeprazole hydrate
WO2007004236A2 (en) 2005-07-04 2007-01-11 Ramu Krishnan Improved drug or pharmaceutical compounds and a preparation thereof
EP1904064A4 (en) * 2005-07-07 2009-12-02 Reddys Lab Ltd Dr OMEPRAZOLE OF FORM B
AU2006274037B2 (en) * 2005-07-26 2012-04-26 Takeda Gmbh Isotopically substituted pantoprazole
EA016814B1 (ru) * 2005-07-26 2012-07-30 Никомед Гмбх Замещенные изотопами ингибиторы протонного насоса
US7601737B2 (en) * 2005-07-26 2009-10-13 Nycomed Gmbh Isotopically substituted proton pump inhibitors
CA2624179A1 (en) * 2005-10-06 2007-04-12 Auspex Pharmaceuticals, Inc. Deuterated inhibitors of gastric h+, k+-atpase with enhanced therapeutic properties
US7576219B2 (en) 2005-10-26 2009-08-18 Hanmi Pharm. Co., Ltd Crystalline S-omeprazole strontium hydrate, method for preparing same, and pharmaceutical composition containing same
AU2006323245B2 (en) 2005-12-05 2011-03-03 Astrazeneca Ab New process for the preparation of esomeprazole non-salt form
EP1801110A1 (en) 2005-12-22 2007-06-27 KRKA, tovarna zdravil, d.d., Novo mesto Esomeprazole arginine salt
US10064828B1 (en) 2005-12-23 2018-09-04 Intellipharmaceutics Corp. Pulsed extended-pulsed and extended-pulsed pulsed drug delivery systems
JP5053865B2 (ja) 2005-12-28 2012-10-24 武田薬品工業株式会社 口腔内崩壊性固形製剤の製造法
US7799925B2 (en) 2005-12-28 2010-09-21 Unión Químico Farmacéutica, S.A. Process for the preparation of the (S)-enantiomer of omeprazole
US9561188B2 (en) * 2006-04-03 2017-02-07 Intellipharmaceutics Corporation Controlled release delivery device comprising an organosol coat
US10960077B2 (en) 2006-05-12 2021-03-30 Intellipharmaceutics Corp. Abuse and alcohol resistant drug composition
US7786309B2 (en) 2006-06-09 2010-08-31 Apotex Pharmachem Inc. Process for the preparation of esomeprazole and salts thereof
US7863330B2 (en) 2006-06-14 2011-01-04 Rottapharm S.P.A. Deloxiglumide and proton pump inhibitor combination in the treatment of gastrointestinal disorders
RU2467747C2 (ru) 2006-07-25 2012-11-27 Векта Лтд. Композиции и способы для ингибирования секреции желудочной кислоты с использованием производных малых дикарбоновых кислот в сочетании с ppi
US20100317689A1 (en) * 2006-09-19 2010-12-16 Garst Michael E Prodrugs of proton pump inhibitors including the 1h-imidazo[4,5-b] pyridine moiety
CA2665226C (en) 2006-10-05 2014-05-13 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
US20090092658A1 (en) * 2007-10-05 2009-04-09 Santarus, Inc. Novel formulations of proton pump inhibitors and methods of using these formulations
EP2486910A3 (en) 2006-10-27 2012-08-22 The Curators Of The University Of Missouri Multi-chambered apparatus comprising a dispenser head
PT2124884T (pt) 2006-12-22 2019-09-17 Ironwood Pharmaceuticals Inc Composições compreendendo sequestradores de ácido biliar para tratar distúrbios esofágicos
EP1947099A1 (en) 2007-01-18 2008-07-23 LEK Pharmaceuticals D.D. Process for solvent removal from omeprazole salts
EP2114919A2 (en) 2007-01-31 2009-11-11 Krka Tovarna Zdravil, D.D., Novo Mesto Process for the preparation of optically pure omeprazole via salt formation with a chiral amine or treatment with an entiomer converting enzyme and chromatographic seperation
US20080194307A1 (en) * 2007-02-13 2008-08-14 Jeff Sanger Sports-based game of chance
CA2678702A1 (en) 2007-02-21 2008-08-28 Cipla Limited Process for the preparation of esomeprazole magnesium dihydrate
JP2010521453A (ja) * 2007-03-15 2010-06-24 サン・ファーマ・アドバンスド・リサーチ・カンパニー・リミテッド 新規プロドラッグ
EP2152691B1 (en) * 2007-06-07 2011-11-23 Aurobindo Pharma Limited An improved process for preparing an optically active proton pump inhibitor
US20100210847A1 (en) * 2007-07-17 2010-08-19 Ranbaxy Laboratories Limited Process for the preparation of pantoprazole sodium and pantoprazole sodium sesquihydrate
WO2009066317A2 (en) * 2007-08-20 2009-05-28 Macleods Pharmaceuticals Limited Process for the preparation of pantoprazole sodium
US8106210B2 (en) 2007-10-08 2012-01-31 Hetero Drugs Limited Polymorphs of esomeprazole salts
CN101450939B (zh) * 2007-12-05 2013-06-19 沈阳药科大学 新型苯并咪唑类化合物
EP2252274A4 (en) 2008-02-20 2011-05-11 Univ Missouri COMPOSITION COMPRISING A COMBINATION OF OMEPRAZOLE AND LANSOPRAZOLE, AND A BUFFER AGENT, AND METHODS OF USING THE SAME
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
JP2011516613A (ja) * 2008-04-15 2011-05-26 シェーリング コーポレイション 好ましくはポサコナゾールおよびｈｐｍｃａｓを含む固体分散物中の経口用薬学的組成物
CL2009000902A1 (es) * 2008-04-15 2010-07-23 Merck Sharp & Dohme Composicion que comprende posaconazol disuelto o disperso molecularmente en un polimero derivado de hidroxipropilcelulosa; formulacion farmaceutica que comprende a la composion; un proceso para preparar a la composicion mediante fusioextrusion; y su uso para tratar una infeccion micotica.
KR101044880B1 (ko) * 2008-06-12 2011-06-28 일양약품주식회사 항궤양제 화합물의 합성에 유용한 중간체의 제조방법
EP2147918A1 (en) 2008-07-21 2010-01-27 LEK Pharmaceuticals D.D. Process for the preparation of S-omeprazole magnesium in a stable form
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
CA2736547C (en) 2008-09-09 2016-11-01 Pozen Inc. Method for delivering a pharmaceutical composition to patient in need thereof
CA2740095A1 (en) * 2008-10-10 2010-04-15 Celtaxsys, Inc. Method of inducing negative chemotaxis
EP2264024A1 (en) 2008-10-14 2010-12-22 LEK Pharmaceuticals d.d. Process for the preparation of enantiomerically enriched proton pump inhibitors
WO2010134099A1 (en) 2009-05-21 2010-11-25 Cadila Healthcare Limited One pot process for preparing omeprazole and related compounds
EP2982978A1 (en) 2009-05-27 2016-02-10 Immunaid Pty Ltd Methods of treating diseases
AU2010263304A1 (en) 2009-06-25 2012-02-02 Astrazeneca Ab Method for treating a patient at risk for developing an NSAID-associated ulcer
EA021112B1 (ru) * 2009-06-25 2015-04-30 Поузен Инк. Способ лечения боли и/или воспаления у пациента, нуждающегося в аспириновой терапии
US8748619B2 (en) 2009-11-12 2014-06-10 Hetero Research Foundation Process for the resolution of omeprazole
WO2011080502A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080500A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
WO2011080501A2 (en) 2009-12-29 2011-07-07 Orexo Ab New pharmaceutical dosage form for the treatment of gastric acid-related disorders
EP2345408A3 (en) 2010-01-08 2012-02-29 Dr. Reddy's Laboratories Ltd. Acid labile drug formulations
CN102140099A (zh) 2010-02-02 2011-08-03 山东轩竹医药科技有限公司 新的吡啶衍生物
US9623622B2 (en) 2010-02-24 2017-04-18 Michael Baines Packaging materials and methods
US20130156720A1 (en) 2010-08-27 2013-06-20 Ironwood Pharmaceuticals, Inc. Compositions and methods for treating or preventing metabolic syndrome and related diseases and disorders
US9233103B2 (en) 2011-03-25 2016-01-12 Takeda Pharmaceuticals U.S.A., Inc. Methods for treating heartburn, gastric bleeding or hemorrhage in patients receiving clopidogrel therapy
CN103826632B (zh) 2011-08-26 2017-04-12 国立大学法人名古屋大学 骨形成促进剂及其用途
MX352760B (es) 2011-09-09 2017-12-07 Merck Sharp & Dohme Corp Star Metodos para tratar infecciones intrapulmonares.
WO2013081566A1 (en) 2011-11-25 2013-06-06 Mahmut Bilgic A formulation comprising benzimidazole
EP2601947A1 (en) 2011-12-05 2013-06-12 Abo Bakr Mohammed Ali Al-Mehdar Fixed-dose combination for treatment of helicobacter pylori associated diseases
MX2014007935A (es) 2011-12-28 2014-11-14 Pozen Inc Composiciones y metodos mejorados para el suministro de omeprazol y de acido acetilsalicilico.
CN102584792B (zh) * 2012-01-06 2014-06-11 南京优科生物医药研究有限公司 制备高纯度的埃索美拉唑盐的方法
CN104203938A (zh) 2012-01-21 2014-12-10 朱比兰特生命科学有限公司 用于制备2-吡啶基甲基亚硫酰基苯并咪唑、它们的类似物和光学活性对映体的方法
US8809314B1 (en) 2012-09-07 2014-08-19 Cubist Pharmacueticals, Inc. Cephalosporin compound
US8476425B1 (en) 2012-09-27 2013-07-02 Cubist Pharmaceuticals, Inc. Tazobactam arginine compositions
AU2014207680B2 (en) 2013-01-15 2018-09-06 Ironwood Pharmaceuticals, Inc. Gastro-retentive sustained-release oral dosage form of a bile acid sequestrant
MX2020004205A (es) 2013-03-15 2021-11-16 Merck Sharp & Dohme Llc Composiciones antibioticas de ceftolozano.
US9872906B2 (en) 2013-03-15 2018-01-23 Merck Sharp & Dohme Corp. Ceftolozane antibiotic compositions
US20140275000A1 (en) 2013-03-15 2014-09-18 Cubist Pharmaceuticals, Inc. Ceftolozane pharmaceutical compositions
GB201306720D0 (en) 2013-04-12 2013-05-29 Special Products Ltd Formulation
WO2015035376A2 (en) 2013-09-09 2015-03-12 Calixa Therapeutics, Inc. Treating infections with ceftolozane/tazobactam in subjects having impaired renal function
US20150094293A1 (en) 2013-09-27 2015-04-02 Calixa Therapeutics, Inc. Solid forms of ceftolozane
US9457011B2 (en) 2014-02-25 2016-10-04 Muslim D. Shahid Compositions and methods for the treatment of acid-related gastrointestinal disorders containing a dithiolane compound and a gastric acid secretion inhibitor
FR3018812A1 (fr) 2014-03-21 2015-09-25 Minakem Nouvelle phase intermediaire de la forme a du sel de magnesium dihydrate d'un enantiomere de l'omeprazole
US10130618B2 (en) 2014-04-11 2018-11-20 Sanovel Ilac Sanayi Ve Ticaret Anonim Sirketi Pharmaceutical combinations of dabigatran and proton pump inhibitors
EP2929885A1 (en) 2014-04-11 2015-10-14 Sanovel Ilac Sanayi ve Ticaret A.S. Pharmaceutical combinations of rivaroxaban and proton pump inhibitors
CN104045627A (zh) * 2014-05-21 2014-09-17 丽珠医药集团股份有限公司 一种奥美拉唑纯化方法
WO2015195684A2 (en) 2014-06-16 2015-12-23 University Of Rochester Small molecule anti-scarring agents
WO2016126625A1 (en) 2015-02-03 2016-08-11 Ironwood Pharmaceuticals, Inc. Methods of treating upper gastrointestinal disorders in ppi refractory gerd
EP3288556A4 (en) 2015-04-29 2018-09-19 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10736855B2 (en) 2016-02-25 2020-08-11 Dexcel Pharma Technologies Ltd. Compositions comprising proton pump inhibitors
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions
AU2017310506B2 (en) * 2016-08-11 2019-11-21 Dmk Pharmaceuticals Corporation Drug compositions
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
KR102409502B1 (ko) * 2016-09-14 2022-06-16 위펑 제인 쳉 D-아미노산 옥시다제 (daao) 저해제로서 신규한 치환된 벤즈이미다졸 유도체
US11564910B2 (en) 2017-12-08 2023-01-31 Adamis Pharmaceuticals Corporation Drug compositions
CN110317164B (zh) * 2019-07-06 2022-08-19 抚州三和医药化工有限公司 一种奥美拉唑中间体的制备方法
EP4284374A1 (en) 2021-01-29 2023-12-06 Abbvie Inc. Methods of administrating elagolix
WO2024075017A1 (en) 2022-10-04 2024-04-11 Zabirnyk Arsenii Inhibition of aortic valve calcification

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1234058A (nl) * 1968-10-21 1971-06-03
SE418966B (sv) * 1974-02-18 1981-07-06 Haessle Ab Analogiforfarande for framstellning av foreningar med magsyrasekretionsinhiberande verkan
US4045564A (en) * 1974-02-18 1977-08-30 Ab Hassle Benzimidazole derivatives useful as gastric acid secretion inhibitors
SE416649B (sv) * 1974-05-16 1981-01-26 Haessle Ab Forfarande for framstellning av foreningar som paverkar magsyrasekretionen
IN148930B (nl) * 1977-09-19 1981-07-25 Hoffmann La Roche

Also Published As

Publication number Publication date
ZA791586B (en) 1980-04-30
NO152216C (no) 1985-08-21
US4337257A (en) 1982-06-29
MY8500074A (en) 1985-12-31
DD142882A5 (de) 1980-07-16
CY1232A (en) 1984-06-29
EP0005129A1 (en) 1979-10-31
EP0005129B1 (en) 1981-04-29
SG63383G (en) 1984-07-27
FI65067B (fi) 1983-11-30
NZ190203A (en) 1984-03-16
DK150510B (da) 1987-03-16
JPS6034956B2 (ja) 1985-08-12
US4508905A (en) 1985-04-02
SU873879A3 (ru) 1981-10-15
JPS6353191B2 (nl) 1988-10-21
SU878196A3 (ru) 1981-10-30
AU4602779A (en) 1979-10-18
US4255431A (en) 1981-03-10
JPS54141783A (en) 1979-11-05
AT389995B (de) 1990-02-26
ATA290483A (de) 1989-08-15
IE790785L (en) 1979-10-14
NO1995006I1 (no) 1995-06-14
NL930074I2 (nl) 1994-02-16
SU873880A3 (ru) 1981-10-15
AU529654B2 (en) 1983-06-16
LT2274B (lt) 1993-12-15
ATA273279A (de) 1983-09-15
NO1994027I1 (no) 1994-12-21
NO152216B (no) 1985-05-13
SU895292A3 (ru) 1981-12-30
CA1127158A (en) 1982-07-06
DE2960293D1 (en) 1981-08-06
BG61492B2 (bg) 1997-09-30
NO840112L (no) 1979-10-16
HK15284A (en) 1984-03-02
HU179022B (en) 1982-08-28
DK151179A (da) 1979-10-15
CS261851B2 (en) 1989-02-10
IE48370B1 (en) 1984-12-26
JPS58192880A (ja) 1983-11-10
NL930075I1 (nl) 1993-09-16
NO152785C (no) 1985-11-20
SE7804231L (sv) 1979-10-15
DK150510C (da) 1987-12-07
FI65067C (fi) 1984-03-12
FI791219A (fi) 1979-10-15
LU88307I2 (fr) 1994-05-04
NL930074I1 (nl) 1993-09-16
AT374471B (de) 1984-04-25
LU88305I2 (fr) 1994-05-04
NO1995005I1 (no) 1995-06-14
NO791227L (no) 1979-10-16
CS254979A2 (en) 1988-07-15
NO152785B (no) 1985-08-12

Similar Documents

Publication Publication Date Title
NL930075I2 (nl) Gesubstitueerde pyridylsulfinylbenzimidazolen met maagzuurafscheidingseigenschappen, farmaceutische preparaten, die deze verbindingen bevatten en tussenprodukten voor de bereiding ervan.
NL930112I2 (nl) Benzazepine-2-onen, werkwijzen ter bereiding daarvan, farmaceutische preparaten die deze verbindingen bevatten, alsmede de verbindingen voor de therapeutische toepassing.
NL930045I2 (nl) 7-Acylamino-3-vinylcefalosporanzuurderivaten, werkwijzen ter bereiding daarvan, farmaceutische preparaten die deze bevatten, hun uitgangsverbindingen en de bereiding daarvan.
NL990027I1 (nl) Bisindoolverbindingen, farmaceutische preparaten die hen bevatten en werkwijze voor hun bereiding.
NL191738C (nl) ML-236B-derivaten, werkwijze voor hun bereiding en farmaceutische preparaten, die deze derivaten bevatten.
NL930106I2 (nl) Ergolineverbindingen, hun bereiding en farmaceutische preparaten die ze bevatten.
MY8500046A (en) N-heterocyclyl-4-piperidinamines, methods for their preparation, pharmaceutical compositions comprising them, intermediates thereof, and methods for the preparation of the intermediates
NL190266C (nl) Aminozuuroplossing voor kankerpatienten.
IT7926362A0 (it) Composto 2-metil-diidropiridinico, procedimenti per la sua preparazione e composizione farmaceutica che lo comprende.
NL7903400A (nl) Werkwijze voor de bereiding van alpha,beta-onverzadigde n-gesubstitueerde carbonzuuramiden.
NL7901241A (nl) Nieuwe gesubstitueerde 2-fenylimino-imidazolidinen, de zuuradditiezouten daarvan, farmaceutische preparaten die deze bevatten, alsmede werkwijze voor de bereiding daarvan.
NL7803165A (nl) Nieuwe 7-aminothiazolylaceetamidocefalosporaan- zuuroximverbindingen, werkwijze voor hun berei- ding en farmaceutische preparaten.
NL7900966A (nl) Nieuwe 3-fenyltetrahydropyridine-derivaten en de zouten daarvan, werkwijze ter bereiding daarvan, de toepassing daarvan als geneesmiddelen en farmaceutische prepara- ten, die deze derivaten bevatten.
NL7902449A (nl) 3-0-(beta-d-glucuronopyranosyl)-sojasapogenol b en zouten daarvan, farmaceutische preparaten die deze verbindingen bevatten alsmede werkwijzen voor de berei- ding van de genoemde verbindingen.
NL7902993A (nl) Nieuwe isochinolinederivaten, de bereiding ervan en farmaceutische preparaten, die de nieuwe isochinoline- derivaten bevatten.
NL7900721A (nl) Nieuwe derivaten van 1-naftylazijnzuur, werkwijze ter bereiding daarvan en farmaceutische preparaten, die deze verbindingen bevatten.
NL186860C (nl) N,n'-bis-(3-picolyl)-4-methoxy-isoftalamidemonohydraat, werkwijze voor de bereiding daarvan en farmaceutische preparaten, die dit bevatten.
RO75739A (ro) Procedeu pentru prepararea unor carbamoil triazolil-o,n-acetali
NL7701695A (nl) Werkwijze voor de bereiding van 2.2-dimethyl- -3-(2'.2'-dichloorvinyl) cyclopropaan-1-carbon- zuur.
NL186699C (nl) Kanamycine-derivaten, werkwijze voor de bereiding daarvan, werkwijze voor de bereiding van farmaceutische preparaten en gevormde farmaceutische preparaten.
IT7984122A0 (it) Procedimento per la produzione diprodotti caseari.
NL190555B (nl) Werkwijze voor de bereiding van 17beta-hydroxy-3-oxo-17alfa-pregn-4-een-21-carbonzuur gamma-lacton, alsmede voor de bereiding van daarbij gevormde tussenprodukten.
NL178002C (nl) Werkwijze voor de bereiding van di-n-propylazijnzuur.
IT7925880A0 (it) Procedimento per la preparazione di 1,2,3-tiadiazol-5-il-uree.
IT7924615A0 (it) Triciclazolo. procedimento per la preparazione di